Hypotensive medication, statins, and the risk of glaucoma

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 7, 2010, Pages 3524-3529

  Owen, Christopher G ^a   Carey, Iain M ^a   Shah, Sunil ^a   de Wilde, Stephen ^a   Wormald, Richard ^b   Whincup, Peter H ^a   Cook, Derek G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONSENSUS; CONTROLLED STUDY; DATA BASE; DRUG USE; FEMALE; GENERAL PRACTICE; GLAUCOMA; HEALTH CARE UTILIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTECTION; RISK ASSESSMENT; SOCIAL STATUS; UNITED KINGDOM; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECT; DRUG UTILIZATION; FACTUAL DATABASE; HEALTH SERVICES RESEARCH; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIMARY HEALTH CARE; RISK; STATISTICS;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; GLAUCOMA; GREAT BRITAIN; HEALTH SERVICES RESEARCH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; ODDS RATIO; PRIMARY HEALTH CARE; RISK ASSESSMENT;

EID: 77955895132     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4821     Document Type: Article

References (42)

1. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266(3):369-374.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.
3. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47(10): 4254-4261.
4. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ. 2008;86(1):63-70.
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
6. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocular hypo-tensive agent. Br J Ophthalmol. 1967;51(4):222-226.
7. Cote G, Drance SM. The effect of propranolol on human intraocular pressure. Can J Ophthalmol. 1968;3(3):207-212.
8. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluoro-photometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27(2):135-142.
9. Wax MB, Molinoff PB. Distribution and properties of beta-adren-ergic receptors in human iris-ciliary body. Invest Ophthalmol Vis Sci. 1987;28(3):420-430.
10. Noack E. Treatment of glaucoma with beta receptor blockers: significance of adrenergic receptors of the beta-2 subtype for their effect on intraocular pressure. Ophthalmologica. 1988;196(2):76-81.
11. Kirwan JF, Nightingale JA, Bunce C, Wormald R. Beta blockers for glaucoma and excess risk of airways obstruction: population based cohort study. BMJ. 2002;325(7377):1396-1397.
12. Gandolfi SA, Chetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. Arch Ophthalmol. 2005;123(1):35-38.
13. Owen CG, Carey IM, DeWilde S, Whincup PH, Wormald R, Cook DG. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol. 2006;90(7):861-868.
14. NICE clinical guideline. Hypertension: Management of Hypertension in Adults in Primary Care. London: National Institute of Clinical Excellence; 2006. Available at http://www.nice.org.uk/CG034. Accessed September 2009.
15. DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart. 2008; 94(1):83-88.
16. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenyla-tion. J Biol Chem. 2007;282(37):26832-26844.
17. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA. 2007;104(33):13444-13449.
18. Bosel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005;92(6):1386-1398.
19. Schmeer C, Kretz A, Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci. 2006;24(2):79-95.
20. Nagaoka T, Takahashi A, Sato E, et al. Effect of systemic administration of simvastatin on retinal circulation. Arch Ophthalmol. 2006;124(5):665-670.
21. Muskens RP, de Voogd S, Wolfs RC, et al. Systemic antihyperten-sive medication and incident open-angle glaucoma. Ophthalmology. 2007;114(12):2221-2226.
22. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107(7):1287-1293.
23. Owen CG, Carey IM, De Wilde S, Whincup PH, Wormald R, Cook DG. Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005. Eye (Lond). 2009;23(5):1098-1110.
24. Carey IM, Cook DG, DeWilde S, et al. Developing a large electronic primary care database (Doctors' Independent Network) for research. Int J Med Inform. 2004;73(5):443-453.
25. DeWilde S, Carey IM, Bremner SA, et al. A comparison of the recording of 30 common childhood conditions in the Doctor's Independent Network and General Practice Research Databases. Health Stat Q. 2004;(22):21-31.
26. CACI. ACORN 2003 User Guide. http://www.caci.co.uk/pdfs/new%20acorn%20brochure.pdf. Accessed December 2007.
27. Smeeth L, Donnan PT, Cook DG. The use of primary care databases: case-control and case-only designs. Fam Pract. 2006; 23(5):597-604.
28. McGwin G, McNeal S, Owsley C, Girkin C, Epstein D, Lee PP. Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol. 2004;122(6):822-826.
29. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92(8):1064-1070.
30. De Wilde S, Carey IM, Harris T, et al. Trends in potentially inappropriate prescribing amongst older UK primary care patients. Pharmacoepidemiol Drug Saf. 2007;16(6):658-667.
31. Langman MJ, Lancashire RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol. 2005;89(8):960-963.
32. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144(3):317-322.
33. Nathanson JA. Human ciliary process adrenergic receptor: pharmacological characterization. Invest Ophthalmol Vis Sci. 1981; 21(6):798-804.
34. Bourgeois H. Epidemiologic and tonometric results of a multi-center study of 5,872 patients with ocular hypertension or open-angle glaucoma treated with betaxolol. Ophtalmologie. 1990;4(4): 323-325.
35. Aprigliano O, Rybin VO, Pak E, Robinson RB, Steinberg SF. beta 1-and beta 2-adrenergic receptors exhibit differing susceptibility to muscarinic accentuated antagonism. Am J Physiol. 1997;272: H2726-H2735.
36. Yu DY, Su EN, Cringle SJ, Alder VA, Yu PK, DeSantis L. Systemic and ocular vascular roles of the antiglaucoma agents beta-adrenergic antagonists and Ca2+ entry blockers. Surv Ophthalmol. 1999; 43(suppl 1):S214-S222.
37. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma: a population-based assessment. Arch Ophthalmol. 1995;113(2):216-221.
38. Klein BE, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol. 2005;89(3):284-287.
39. Osborne NN, Wood JP, Chidlow G, Casson R, DeSantis L, Schmidt KG. Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res Bull. 2004;62(6):525-528.
40. Rahim SA, Sahlas DJ, Shadowitz S. Blinded by pressure and pain. Lancet. 2005;365(9478):2244.
41. Song J, Deng PF, Stinnett SS, Epstein DL, Rao PV. Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci. 2005;46(7):2424-2432.
42. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88(1):64-75.